Nicotine patch demonstrated to be safe in smokers with CAD
Nicotine patches used for smoking cessation are safe in patients with coronary artery disease (CAD) and active stress-induced myocardial ischemia, according to the results of a randomized trial.
Key Points
Nicotine patches used for smoking cessation are safe in patients with coronary artery disease (CAD) and active stress-induced myocardial ischemia, according to Monika J. Leja, MD.
Dr Leja and colleagues at The Methodist DeBakey Heart Center in Houston, Tex, studied 55 heavy smokers with >9% perfusion defect size on single photon emission computed tomography (SPECT), randomizing them to a 21-mg nicotine patch (n=28) or a placebo patch (n=27). The participants were not required to stop smoking to be included in the trial.
The safety of nicotine patches in patients with CAD who continue to smoke is uncertain because nicotine is known to increase heart rate and blood pressure, and may induce vasoconstriction, Dr Leja said.
As expected, nicotine levels increased significantly in the nicotine patch wearers but despite this increase, there was no significant change in the total or ischemic perfusion defect size from baseline in the active patch wearers, compared with the placebo patch wearers.
The total perfusion defect size did not change significantly in either group from baseline to Week 1. The total perfusion defect size decreased from 24.8% at baseline to 24.2% at Week 1 in the participants assigned to the nicotine patch, and from 21.1% at baseline to 18.6% at Week 1 in the participants assigned to the placebo patch.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
